HRP20120558T1 - Kapa-selektivni antagonist opioidnih receptora - Google Patents
Kapa-selektivni antagonist opioidnih receptora Download PDFInfo
- Publication number
- HRP20120558T1 HRP20120558T1 HRP20120558AT HRP20120558T HRP20120558T1 HR P20120558 T1 HRP20120558 T1 HR P20120558T1 HR P20120558A T HRP20120558A T HR P20120558AT HR P20120558 T HRP20120558 T HR P20120558T HR P20120558 T1 HRP20120558 T1 HR P20120558T1
- Authority
- HR
- Croatia
- Prior art keywords
- disorder
- pharmaceutically acceptable
- chosen
- acceptable salt
- compound according
- Prior art date
Links
- 229940123257 Opioid receptor antagonist Drugs 0.000 title 1
- 239000003401 opiate antagonist Substances 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000019901 Anxiety disease Diseases 0.000 claims 6
- 208000020401 Depressive disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- ZHPMYDSXGRRERG-DEOSSOPVSA-N aticaprant Chemical group CC1=CC(C)=CC([C@H]2N(CCC2)CC=2C=CC(OC=3C(=CC(=CC=3)C(N)=O)F)=CC=2)=C1 ZHPMYDSXGRRERG-DEOSSOPVSA-N 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 229960000836 amitriptyline Drugs 0.000 claims 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 2
- 239000002249 anxiolytic agent Substances 0.000 claims 2
- 230000000949 anxiolytic effect Effects 0.000 claims 2
- 229960004606 clomipramine Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims 2
- 229960005426 doxepin Drugs 0.000 claims 2
- 208000024732 dysthymic disease Diseases 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 229960004801 imipramine Drugs 0.000 claims 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 2
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 201000001716 specific phobia Diseases 0.000 claims 2
- 150000003512 tertiary amines Chemical class 0.000 claims 2
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- ZHPMYDSXGRRERG-UHFFFAOYSA-N 4-[4-[[2-(3,5-dimethylphenyl)pyrrolidin-1-yl]methyl]phenoxy]-3-fluorobenzamide Chemical compound CC1=CC(C)=CC(C2N(CCC2)CC=2C=CC(OC=3C(=CC(=CC=3)C(N)=O)F)=CC=2)=C1 ZHPMYDSXGRRERG-UHFFFAOYSA-N 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 229960004782 chlordiazepoxide Drugs 0.000 claims 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (10)
1. Spoj, naznačen time što je 3-fluor-4-[4-[2-(3,5-dimetilfenil)pirolidin-1-ilmetil]fenoksi]benzamid, ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skadu s patentnim zahtjevom 1, naznačen time što je (S)-3-fluor-4-[4-[2-(3,5-dimetilfenil)pirolidin-1-ilmetil]fenoksi]benzamid, ili njegova farmaceutski prihvatljiva sol.
3. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegovu farmaceutski prihvatljivu sol, uz farmaceutski prihvatljivu podlogu, razrjeđivač i/ili pomoćnu tvar.
4. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
5. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju poremećaja upotrebe etanola.
6. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju:
a) anksioznog poremećaja, kojeg se bira između paničnog poremećaja, opsesivno-kompulzivnog poremećaja, socijalne fobije, generaliziranog anksioznog poremećaja, specifične fobije i posttraumatskog stresnog poremećaja; ili
b) depresivne bolesti, koju se bira između velike depresije, distimije i bipolarnog poremećaja; ili
c) anksioznog poremećaja, kojeg se bira iz a) i depresivne bolesti, koju se bira iz b); ili
d) poremećaja upotrebe etanola i anksioznog poremećaja, kojeg se bira iz a); ili
e) poremećaja upotrebe etanola i depresivne bolesti, koju se bira iz b); ili
f) poremećaja upotrebe etanola i anksioznog poremećaja, kojeg se bira iz a) i depresivne bolesti, koju se bira iz b); ili
g) shizofrenije; ili
h) poremećaja upotrebe etanola i shizofrenije.
7. Farmaceutski pripravak, naznačen time što sadrži terapijski djelotvornu količinu (S)-3-fluor-4-[4-[2-(3,5-dimetilfenil)pirolidin-1-ilmetil]fenoksi]benzamida, ili njegove farmaceutski prihvatljive soli, i terapijski djelotvornu količinu tercijarno aminskog tricikličkog inhibitora povratnog unosa noradrenalina, kojeg se bira između amitriptilina, klomipramina, doksepina, imipramina i (+)-trimipramina, ili njegove farmaceutski prihvatljive soli, uz farmaceutski prihvatljivu podlogu, razrjeđivač i/ili pomoćnu tvar.
8. (S)-3-Fluor-4-[4-[2-(3,5-dimetilfenil)pirolidin-1-ilmetil]fenoksi]benzamid, ili njegova farmaceutski prihvatljiva sol, i tercijarnoaminski triciklički inhibitor povratnog unosa noradrenalina, kojeg se bira između amitriptilina, klomipramina, doksepina, imipramina i (+)-trimipramina, ili njegove farmaceutski prihvatljive soli, naznačen time što je namijenjen upotrebi u liječenju:
a) poremećaja upotrebe etanola, ili
b) depresivne bolesti, koju se bira između velike depresije, distimije i bipolarnog poremećaja, ili
c) poremećaja upotrebe etanola i depresivne bolesti, koju se bira iz b).
9. Spoj, koji je (S)-3-fluor-4-[4-[2-(3,5-dimetilfenil)pirolidin-1-ilmetil]fenoksi]benzamid, ili njegova farmaceutski prihvatljiva sol, i benzodiazepinski anksiolitik, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju:
a) anksioznog poremećaja, kojeg se bira između paničnog poremećaja, opsesivno-kompulzivnog poremećaja, socijalne fobije, generaliziranog anksioznog poremećaja, specifične fobije i posttraumatskog stresnog poremećaja, ili
b) poremećaja upotrebe etanola i anksioznog poremećaja, kojeg se bira iz a).
10. Spoj u skladu s patentnim zahtjevom 9, naznačen time što je anksiolitik klordiazepoksid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08380012 | 2008-01-22 | ||
| US3912108P | 2008-03-25 | 2008-03-25 | |
| PCT/US2009/030811 WO2009094260A1 (en) | 2008-01-22 | 2009-01-13 | Kappa selective opioid receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120558T1 true HRP20120558T1 (hr) | 2012-10-31 |
Family
ID=40876972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120558AT HRP20120558T1 (hr) | 2008-01-22 | 2012-07-06 | Kapa-selektivni antagonist opioidnih receptora |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7709522B2 (hr) |
| EP (1) | EP2252581B1 (hr) |
| JP (1) | JP5345637B2 (hr) |
| KR (1) | KR101172170B1 (hr) |
| CN (1) | CN101925576B (hr) |
| AR (1) | AR070158A1 (hr) |
| AU (1) | AU2009206653B2 (hr) |
| BR (1) | BRPI0907382B8 (hr) |
| CA (1) | CA2713025C (hr) |
| CO (1) | CO6290644A2 (hr) |
| CY (1) | CY1113071T1 (hr) |
| DK (1) | DK2252581T3 (hr) |
| DO (1) | DOP2010000222A (hr) |
| EA (1) | EA017484B1 (hr) |
| EC (1) | ECSP10010365A (hr) |
| ES (1) | ES2388708T3 (hr) |
| HK (1) | HK1146822A1 (hr) |
| HR (1) | HRP20120558T1 (hr) |
| IL (1) | IL206038A (hr) |
| JO (1) | JO2797B1 (hr) |
| MA (1) | MA32751B1 (hr) |
| MX (1) | MX2010007849A (hr) |
| MY (1) | MY163014A (hr) |
| NZ (1) | NZ586225A (hr) |
| PE (1) | PE20091317A1 (hr) |
| PL (1) | PL2252581T3 (hr) |
| PT (1) | PT2252581E (hr) |
| SI (1) | SI2252581T1 (hr) |
| TN (1) | TN2010000306A1 (hr) |
| TW (1) | TWI422369B (hr) |
| UA (1) | UA100715C2 (hr) |
| WO (1) | WO2009094260A1 (hr) |
| ZA (1) | ZA201003908B (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2252581T3 (da) * | 2008-01-22 | 2012-07-16 | Lilly Co Eli | Kappa-selektiv opioidreceptorantagonist |
| AU2009206936A1 (en) * | 2008-01-22 | 2009-07-30 | Takeda Pharmaceutical Company Limited | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them |
| WO2013040321A1 (en) * | 2011-09-15 | 2013-03-21 | University Of Kansas | Kappa opioid receptor effectors and uses thereof |
| WO2013042054A1 (en) | 2011-09-19 | 2013-03-28 | Carmel - Haifa University Economic Corporation Ltd. | Buprenorphine for the treatment of acute suicidality |
| US9512105B2 (en) | 2011-12-09 | 2016-12-06 | Research Triangle Institute | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| US9283196B1 (en) | 2013-01-30 | 2016-03-15 | MediSynergics, LLC | Cycloalkyl-diamines for CNS disorders |
| AU2014268361B2 (en) * | 2013-05-24 | 2018-09-06 | Alkermes Pharma Ireland Limited | Morphan and morphinan analogues, and methods of use |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| KR102656163B1 (ko) | 2017-03-17 | 2024-04-08 | 더 스크립스 리서치 인스티튜트 | 카파 오피오이드 수용체 길항제 및 그와 관련된 제품 및 방법 |
| JP6480616B1 (ja) | 2018-02-08 | 2019-03-13 | 有限会社 ディオン光学技研 | 照準スコープ |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| KR20240004857A (ko) | 2021-05-04 | 2024-01-11 | 얀센 파마슈티칼즈, 인코포레이티드 | 우울증 치료를 위한 조성물 및 방법 |
| WO2023131921A1 (en) * | 2022-01-10 | 2023-07-13 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023131920A1 (en) * | 2022-01-10 | 2023-07-13 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| TW202400135A (zh) * | 2022-03-07 | 2024-01-01 | 美商健生醫藥公司 | 包含阿替卡普蘭之組成物 |
| US20230348377A1 (en) * | 2022-03-07 | 2023-11-02 | Janssen Pharmaceuticals, Inc. | Pure forms of crystalline aticaprant |
| JP7176142B1 (ja) | 2022-03-09 | 2022-11-21 | 直迪 清瀬 | 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| ES2189759T3 (es) * | 1999-05-12 | 2003-07-16 | Hoffmann La Roche | Derivados de imidazoiacepina. |
| WO2002029418A1 (en) * | 2000-10-05 | 2002-04-11 | Hanns Mohler | Selective anxiolytic therapeutic agents |
| US6528518B2 (en) | 2000-12-21 | 2003-03-04 | The Mclean Hospital Corporation | Treatment of depression with kappa receptor antagonists |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| KR100865410B1 (ko) * | 2002-03-28 | 2008-10-24 | 위시스 테크놀로지 파운데이션, 인크. | 진정 및 운동실조 효과가 감소된 항불안제 |
| CA2499690C (en) * | 2002-09-19 | 2011-05-24 | Eli Lilly And Company | Diaryl ethers as opioid receptor antagonist |
| BRPI0407616A (pt) | 2003-03-07 | 2006-02-14 | Lilly Co Eli | composto, composição farmacêutica, método para bloquear uma combinação de receptor de mu, capa, delta (heterodìmero) deste em mamìferos, método para tratar ou prevenir obesidade e doenças relacionadas, uso de um composto, e método de suprimir o apetite em um paciente em necessidade deste" |
| JP2006519855A (ja) | 2003-03-07 | 2006-08-31 | イーライ リリー アンド カンパニー | オピオイド受容体アンタゴニスト |
| EP1697307B1 (en) | 2003-12-12 | 2014-03-12 | Eli Lilly & Company | Opioid receptor antagonists |
| CN1894240A (zh) | 2003-12-22 | 2007-01-10 | 伊莱利利公司 | 阿片受体拮抗剂 |
| EP1730140B1 (en) | 2004-03-12 | 2008-06-25 | Eli Lilly And Company | Opioid receptor antagonists |
| US7381750B2 (en) | 2004-03-12 | 2008-06-03 | Eli Lilly And Company | Amino-phenoxymethyl-benzamide opioid receptor antagonists |
| EP1729759A4 (en) | 2004-03-12 | 2008-04-02 | Mclean Hospital Corp | SALVINORIN DERIVATIVES AND USES THEREOF |
| EP1735268B1 (en) | 2004-03-15 | 2012-02-15 | Eli Lilly And Company | Opioid receptor antagonists |
| WO2005090303A1 (en) | 2004-03-15 | 2005-09-29 | Eli Lilly And Company | 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity |
| WO2007067714A2 (en) | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| WO2007115975A2 (de) | 2006-04-04 | 2007-10-18 | Holger Lars Hermann | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
| CN103980151A (zh) | 2006-08-09 | 2014-08-13 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物 |
| US20100222345A1 (en) | 2006-08-09 | 2010-09-02 | Caroline Jean Diaz | Novel compounds as antagonists or inverse agonists for opioid receptors |
| KR20090051778A (ko) | 2006-09-08 | 2009-05-22 | 화이자 프로덕츠 인코포레이티드 | 다이아릴 에터 유도체 및 이의 용도 |
| DK2252581T3 (da) * | 2008-01-22 | 2012-07-16 | Lilly Co Eli | Kappa-selektiv opioidreceptorantagonist |
-
2009
- 2009-01-13 DK DK09703808.7T patent/DK2252581T3/da active
- 2009-01-13 ES ES09703808T patent/ES2388708T3/es active Active
- 2009-01-13 CA CA2713025A patent/CA2713025C/en active Active
- 2009-01-13 AU AU2009206653A patent/AU2009206653B2/en active Active
- 2009-01-13 BR BRPI0907382A patent/BRPI0907382B8/pt active IP Right Grant
- 2009-01-13 WO PCT/US2009/030811 patent/WO2009094260A1/en active Application Filing
- 2009-01-13 KR KR1020107016401A patent/KR101172170B1/ko active IP Right Grant
- 2009-01-13 PL PL09703808T patent/PL2252581T3/pl unknown
- 2009-01-13 AR ARP090100098A patent/AR070158A1/es not_active Application Discontinuation
- 2009-01-13 NZ NZ586225A patent/NZ586225A/en unknown
- 2009-01-13 PE PE2009000036A patent/PE20091317A1/es active IP Right Grant
- 2009-01-13 SI SI200930326T patent/SI2252581T1/sl unknown
- 2009-01-13 JO JO200915A patent/JO2797B1/en active
- 2009-01-13 EP EP09703808A patent/EP2252581B1/en active Active
- 2009-01-13 MY MYPI2010003437A patent/MY163014A/en unknown
- 2009-01-13 US US12/352,869 patent/US7709522B2/en active Active
- 2009-01-13 UA UAA201008931A patent/UA100715C2/ru unknown
- 2009-01-13 CN CN2009801026504A patent/CN101925576B/zh active Active
- 2009-01-13 TW TW098101083A patent/TWI422369B/zh active
- 2009-01-13 MX MX2010007849A patent/MX2010007849A/es active IP Right Grant
- 2009-01-13 JP JP2010543182A patent/JP5345637B2/ja active Active
- 2009-01-13 EA EA201070877A patent/EA017484B1/ru not_active IP Right Cessation
- 2009-01-13 PT PT09703808T patent/PT2252581E/pt unknown
-
2010
- 2010-04-09 US US12/757,451 patent/US8173695B2/en active Active
- 2010-05-27 IL IL206038A patent/IL206038A/en active IP Right Grant
- 2010-06-01 ZA ZA2010/03908A patent/ZA201003908B/en unknown
- 2010-06-30 TN TN2010000306A patent/TN2010000306A1/fr unknown
- 2010-07-19 MA MA33041A patent/MA32751B1/fr unknown
- 2010-07-20 DO DO2010000222A patent/DOP2010000222A/es unknown
- 2010-07-22 EC EC2010010365A patent/ECSP10010365A/es unknown
- 2010-08-12 CO CO10099271A patent/CO6290644A2/es active IP Right Grant
-
2011
- 2011-01-24 HK HK11100691.9A patent/HK1146822A1/xx unknown
-
2012
- 2012-07-06 HR HRP20120558AT patent/HRP20120558T1/hr unknown
- 2012-08-24 CY CY20121100765T patent/CY1113071T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120558T1 (hr) | Kapa-selektivni antagonist opioidnih receptora | |
| JP2011524850A5 (hr) | ||
| JP2011148799A5 (hr) | ||
| CY1117978T1 (el) | Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a | |
| EA201401150A1 (ru) | Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств | |
| NZ585085A (en) | Method of treating arthritis using arylsulfonamide compounds | |
| NO343929B3 (no) | 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte | |
| HRP20151017T1 (hr) | Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida | |
| AR079198A1 (es) | Sales de 4-(2-((5-metil-1-(2-naftalenil) -1h pirazol -3- il)oxi) etil) morfolina | |
| NO2017063I1 (no) | Kombinasjon av: - rilpivirine hydroklorid etter en terapeutisk ekvivalent form derav, - emtricitabine og - tenofovir alafenamid eller farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamidfumarat | |
| JP2007519754A5 (hr) | ||
| NO20071300L (no) | Trifluormetylsubstituerte benzamider som kinaseinhibitorer. | |
| NZ603364A (en) | Inhibitors of arginase and their therapeutic applications | |
| ATE397605T1 (de) | Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol | |
| HRP20140880T1 (hr) | Tekuä†a formulacija soli 1-/2-(2,4 dimetilfenilsulfanil)fenil/piperazina | |
| NO20063597L (no) | Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| JP2009541443A5 (hr) | ||
| HK1144940A1 (en) | Amine salts of a crth2 antagonist | |
| RU2016149804A (ru) | Производные бензолсульфонамида и их применение в качестве модуляторов орфанного рецептора y, связанного с ретиноевой кислотой | |
| NZ598083A (en) | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine | |
| CL2010000059A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-diflurobenzamida o una sal farmaceuticamente aceptable; forma polimorfica de la sal clorhidrato; composicion farmaceutica; y su uso para tratar una enfermedad del sistema nervioso central tal como dolor, sindrome metabolico, inflamacion, alzheimer. | |
| HRP20201405T1 (hr) | Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a | |
| HRP20110333T1 (hr) | 4[(3-fluorfenoksi)fenilmetil]piperidin-metansulfonat: upotreba, postupci sinteze i farmaceutski pripravci | |
| BR112012028992B8 (pt) | 1 - [(4-hidroxipiredina-4-il)metil]piridina-2 (1h) -ona, método de preparação e utilização dos mesmos | |
| RU2019104946A (ru) | Применение производного хромона в качестве антагониста дофаминового рецептора d3 для лечения расстройства аутистического спектра |